Recently raised circa £1.3 million at 4p. Market cap a micro £4 million and partnered with National Cancer Institute in US.
Sentiment towards small pharmas improving all the time so the right share in the right places is FAB. Easy 100% first up.
Wow! Great find Haywain.
As those of us who are here to support a company finding cures for terrible diseases such as claimed my beautiful sister recently and also making investors willing to risk their money enormous profits then this article tells it as it is.
The upside is truly phenomenal and is happening now. Personally taking ever y opportunity to buy more like into a monthly unit trust at these prices cause when it turns on news as the article rightly says the upside is going to be dramatic. Good luck all.
Just a thought. The CFO mentioned the circa 4 million in warrants that Riverfort have at various prices I think starting at 10p.
He mentioned these could be reviewed/adjusted so it could be the funding will come from River exercising their warrants at a lower price meaning the company gets their cash raise, River will dispose of their final shares and then away we go.
Lovely update thank you.
Market cap circa £5 million. Cash in bank £1.2 million so circa a quarter of market cap in cash.
A range of funding options being considered and cash to be used for FDA submission etc which will provide explosive growth. Rainbow chasers fail to look beyond the noise.
ATB to genuine investors.
JHFH - you took the words. Having just listened to it was going to make that point which is the strongest part of the interview for me.
He made clear how difficult funding had been for all small cap biotechs yet they got a good raise away and now investors and other ‘entities’ coming to them.
Can see a strategic investor/ JV being announced. Clinical trial company plus he also mentioned options to sell off parts. Imagine what the other two parts are each worth?!
IMHO - the rise to 6p recently will fade as this rockets. Watch this space. Bought some more thank you.
Cheadle - spot on but I would add this.
In the RNS announcing the collaboration with NCI USA there is minimal funds required from FAB and yet we have a whale of an institution willing to engage and get involved in the ONLY Optimal platform in the world!
Then look at the market cap and now cash positive then you and I see why the multibagger upside is approaching based on our research.
Onwards and very upwards.
So tomorrow is the 10am meeting to approve the increase in shares. This triggers the placing at 4p which raises circa £1.35 million. Add the recent tax credit at circa £280,000 and you have over £1.6 million in cash.
Market cap just over £2 million with tie up with National Cancer Institute of US. This is getting ready to re rate big time IMHO.
Good luck all.
I had so much faith in this company. Sold on recent spike to recover my money.
Just no end in sight to monetise the assets.
Can’t sell Microsalt for a year, BELL and LUCYD need time to recover and clear Guident continues to need funding and now a new company that clearly is going to need funds.
So corrupt that the price dropped over last few days then this placing.
Good luck to the faithful.
Just a thought…… Top 5 worldwide bakery companies…..
1. Nestle … net sales 94 billion dollars pa
2. PepsiCo (already rumoured as the company we supply) 86 billion
3.Arca continental Mexico (note we also been mentioned as involved in the country …53 billion
4. Mondelez International US …31 billion
5. Kraft Heinz … 26 billion
Wakey wakey market……Microsalt can produce anywhere in the world and at scale. Already with a whale and the others will not want to be left behind. Worth £3 plus even at this stage of growth. IMHO
So now already being marketed in UAE and therefore throughout Middle East which will surely follow.
Imagine when a distribution contract is made in China with their birth rate! Plus US next up me thinks.
Wakey wakey market
Wake
In addition, the Company is pleased to announce that it has recently signed a master services agreement (the "MSA") with a leading global provider of diagnostics solutions (the "Partner"). The MSA provides a framework under which it is anticipated that Fusion would provide antibody discovery, engineering and supply services to the Partner for diagnostic purposes. The Partner is a blue-chip company in the diagnostics sector, an industry which the Directors consider has significant potential for Fusion's growth prospects. Any work undertaken under the MSA will be subject to the receipt of separate purchase orders from the Partner.